While the Drug Enforcement Administration (“DEA”) prosecuted far fewer administrative actions in FY2012 than FY2011, the Agency nonetheless continued to be very active in investigating pharmaceutical diversion cases. The highly publicized and unprecedented actions taken by DEA in FY2012 provide valuable insight to where the DEA may focus its enforcement efforts in 2013. The “DEA